At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer.
In Brief
A Phase 3 clinical trial evaluating Bevacizumab, Placebo, and 2 other interventions for Gastric Cancer. Completed, enrolled 202 participants across 14 sites.
Detailed Summary
This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior chemotherapy for advanced or metastatic gastric cancer. Participants will be randomized to one of two treatment groups Bevacizumab + Capecitabine/Cisplatin (experimental arm) or Placebo + Capecitabine/Cisplatin (control arm).
Study Details
Timeline
Interventions
7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
Placebo matched to bevacizumab on Day 1 of every 3-week cycle
1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles